Viking Therapeutics, Inc. (VKTX) Forms $5.80 Double Top; Logan Capital Management Upped Hanesbrands (HBI) Holding By $302,208

Viking Therapeutics, Inc. (VKTX) formed double top with $5.97 target or 3.00% above today’s $5.80 share price. Viking Therapeutics, Inc. (VKTX) has $272.88M valuation. The stock increased 3.02% or $0.17 during the last trading session, reaching $5.8. About 1.71M shares traded or 21.42% up from the average. Viking Therapeutics, Inc. (NASDAQ:VKTX) has risen 5.04% since March 11, 2017 and is uptrending. It has underperformed by 11.66% the S&P500.

Logan Capital Management Inc increased Hanesbrands Inc (HBI) stake by 2.86% reported in 2017Q3 SEC filing. Logan Capital Management Inc acquired 12,592 shares as Hanesbrands Inc (HBI)’s stock declined 1.43%. The Logan Capital Management Inc holds 452,534 shares with $11.15 million value, up from 439,942 last quarter. Hanesbrands Inc now has $7.21 billion valuation. The stock increased 2.41% or $0.47 during the last trading session, reaching $20.01. About 5.86M shares traded. Hanesbrands Inc. (NYSE:HBI) has declined 23.23% since March 11, 2017 and is downtrending. It has underperformed by 39.93% the S&P500.

Analysts await Viking Therapeutics, Inc. (NASDAQ:VKTX) to report earnings on March, 20. They expect $-0.19 EPS, down 5.56% or $0.01 from last year’s $-0.18 per share. After $-0.22 actual EPS reported by Viking Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -13.64% EPS growth.

Among 4 analysts covering Viking Therapeutics (NASDAQ:VKTX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Viking Therapeutics had 12 analyst reports since April 7, 2016 according to SRatingsIntel. H.C. Wainwright maintained the shares of VKTX in report on Thursday, August 10 with “Buy” rating. The rating was maintained by Roth Capital with “Buy” on Wednesday, November 29. Roth Capital maintained the shares of VKTX in report on Thursday, March 8 with “Buy” rating. The rating was initiated by Roth Capital on Tuesday, November 21 with “Buy”. The rating was maintained by Maxim Group with “Buy” on Thursday, August 10. The rating was maintained by Maxim Group with “Buy” on Wednesday, July 12. The firm has “Buy” rating by H.C. Wainwright given on Monday, July 17. H.C. Wainwright reinitiated the stock with “Buy” rating in Friday, November 10 report. The stock has “Buy” rating by Laidlaw on Thursday, August 11. Maxim Group maintained Viking Therapeutics, Inc. (NASDAQ:VKTX) on Tuesday, June 6 with “Buy” rating.

Among 19 analysts covering Hanesbrands (NYSE:HBI), 11 have Buy rating, 0 Sell and 8 Hold. Therefore 58% are positive. Hanesbrands had 57 analyst reports since September 17, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Wednesday, September 27 by Cowen & Co. Morgan Stanley maintained Hanesbrands Inc. (NYSE:HBI) on Monday, August 7 with “Equal-Weight” rating. The rating was maintained by Oppenheimer on Tuesday, August 29 with “Buy”. Buckingham Research maintained Hanesbrands Inc. (NYSE:HBI) on Thursday, November 2 with “Buy” rating. Nomura downgraded the stock to “Neutral” rating in Thursday, September 21 report. On Monday, December 12 the stock rating was upgraded by CL King to “Buy”. The company was upgraded on Monday, December 12 by DA Davidson. The stock has “Equal-Weight” rating by Morgan Stanley on Monday, February 27. The rating was maintained by UBS with “Buy” on Friday, February 3. The stock of Hanesbrands Inc. (NYSE:HBI) earned “Buy” rating by Brean Capital on Monday, July 17.

Since February 15, 2018, it had 0 insider purchases, and 1 sale for $1.07 million activity. Upchurch W Howard Jr sold $1.07M worth of stock or 51,743 shares.